Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

@article{Pinto2020CrossneutralizationOS,
  title={Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody},
  author={Dora Pinto and Young-Jun Park and Martina Beltramello and Alexandra C. Walls and M. Alejandra Tortorici and Siro Bianchi and Stefano Jaconi and Katja Culap and Fabrizia Zatta and Anna De Marco and Alessia Peter and Barbara Guarino and Roberto Spreafico and Elisabetta Cameroni and James Brett Case and Rita E Chen and Colin Havenar-Daughton and Gyorgy Snell and Amalio Telenti and Herbert W. Virgin and Antonio Lanzavecchia and Michael Steven Diamond and Katja Fink and David Veesler and Davide Corti},
  journal={Nature},
  year={2020},
  volume={583},
  pages={290-295}
}
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020 1 , 2 . Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing… 
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
TLDR
As several antibodies binding specific regions of the RBD and NTD show loss-of-neutralization potency in vitro against emerging variants, updated mAb cocktails, targeting of highly conserved regions, enhancement of mAb potency, or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
TLDR
2-36 represents a strategic reserve drug candidate for the prevention and treatment of possible diseases caused by pre-emergent SARS-related coronaviruses and its epitope defines a promising target for the development of a pan-sarbecovirus vaccine.
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
TLDR
Taken together, 2–36 represents a strategic reserve drug candidate for the prevention and treatment of possible diseases caused by pre-emergent SARS-related coronaviruses and its epitope defines a promising target for the development of a pan-sarbecovirus vaccine.
Antibody cocktail effective against variants of SARS-CoV-2
TLDR
These antibody cocktails are highly promising candidate tools for controlling new SARS-CoV-2 variants, including Delta, and exhibited potent prophylactic and therapeutic effects in Delta Sars-Cov-2 variant-infected hamsters.
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
TLDR
A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres, suggesting both of these regions at the top of the viral spike are immunogenic.
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
TLDR
A systemic overview of SARS-CoV-2 specific or cross-reactive NAbs and their structures, functions and neutralization mechanisms are provided and evidence is urgently needed to the development of antibody therapeutic interventions that are likely required to reduce the global burden of COVID-19.
Antibodies and Vaccines Target RBD of SARS-CoV-2
TLDR
This review focuses on neutralizing antibodies that are targeting RBD as well as the vaccine based on RBD under current development, both of which are expected to be safer than others.
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
TLDR
Some of the most promising broadly neutralizing antibodies obtained from plasma of patients that recovered from early variants of SARS-CoV-2 that may be effective against emerging new variants of the virus are reviewed.
Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells
TLDR
A panel of synthetic monoclonal antibodies are described, built on a human IgG framework, that bind to the spike protein of SARS-CoV-2 (the causative agent of COVID-19), compete for ACE2 binding, and potently inhibit Sars-Cov-2.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 90 REFERENCES
Human neutralizing antibodies elicited by SARS-CoV-2 infection
TLDR
In a study of antibodies isolated from patients infected with SARS-CoV-2, antibodies that potently neutralized the virus competed with angiotensin-converting enzyme 2 for binding to the receptor-binding domain of the viral spike protein, suggesting that antibodies that disrupt this interaction could be developed to treat Sars-Cov-2 infection.
A human monoclonal antibody blocking SARS-CoV-2 infection
TLDR
A human monoclonal antibody is reported capable of neutralizing both authentic SARS-CoV and SARS -CoV-2 by targeting a common epitope on these viruses.
Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
TLDR
Results suggest that antibody response to RBDs is viral species-specific while that cross-recognition target regions outside the RBD are cross- Recognition target areas outside the SARS-CoV-2.
A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
TLDR
It is reported that this first-ever resolution of a human antibody in complex with SARS-CoV-2 and the broad reactivity of this set of antibodies to a conserved betacoronavirus epitope will allow antigenic assessment of vaccine candidates, and provide a framework for accelerated vaccine, immunotherapeutic and diagnostic strategies against Sars-Cov-2.
Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals
TLDR
Rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Structural basis of receptor recognition by SARS-CoV-2
TLDR
This study determines the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 (engineered to facilitate crystallization) in complex with ACE2 and sheds light on the structural features that increase its binding affinity to ACE2.
Viral Architecture of SARS-CoV-2 with Post-Fusion Spike Revealed by Cryo-EM
TLDR
The morphology of virion observed in the result indicates that the S protein of SARS-CoV-2 is in post-fusion state, with S1 disassociated, which could provide an important information for the identification and relevant clinical research of this new coronavirus.
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
TLDR
The crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein at 3.1-angstrom resolution is determined, providing molecular insights into antibody recognition of Sars-Cov-2.
...
1
2
3
4
5
...